CRESCENT BIOPHARMA, INC. (CBIO) Net income 2016–2025
CRESCENT BIOPHARMA, INC. (CBIO) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$153.9MFY2025 · since FY2016: -$31.8M → -$153.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$153.9M | -306.4% |
| FY2024 | -$37.9M | -2.7% |
| FY2023 | -$36.9M | +21.0% |
| FY2022 | -$46.7M | +26.4% |
| FY2021 | -$63.4M | -24.3% |
| FY2020 | -$51.0M | +11.9% |
| FY2019 | -$57.9M | -19.9% |
| FY2018 | -$48.3M | -45.0% |
| FY2017 | -$33.3M | -4.6% |
| FY2016 | -$31.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More CBIO financial trends
CBIO RevenueCBIO Net marginCBIO Gross profitCBIO Gross marginCBIO Operating incomeCBIO Operating marginCBIO Operating cash flowCBIO Free cash flowCBIO Capital expendituresCBIO Return on equityCBIO Stock buybacksCBIO Dividends paidCBIO Total assetsCBIO Total liabilitiesCBIO Shareholders’ equityCBIO overview →